The Rising Importance of Proton Magnetic Resonance Spectroscopy in the Diagnosis of Selected Neurodegenerative Diseases of the Brain
DOI:
https://doi.org/10.12775/JEHS.2024.72.51253Keywords
proton magnetic resonance spectroscopy, ¹H-MRS, neurodegenerative diseases, metabolitesAbstract
Introduction: Neurodegenerative diseases pose a significant diagnostic challenge due to the increasing elderly population and the rising prevalence of these conditions.
State of Knowledge: Differential diagnosis among these diseases is particularly challenging; thus, numerous clinical trials have been conducted to identify markers that could facilitate accurate disease diagnosis. Among various diagnostic approaches, imaging techniques play a crucial role, especially magnetic resonance imaging (MRI), which includes advanced modalities such as proton magnetic resonance spectroscopy (¹H-MRS). ¹H-MRS offers a non-invasive assessment of neurometabolite profiles, providing critical information that aids in precise diagnosis.
Conclusions: With ongoing clinical trials, the importance of ¹H-MRS in diagnosing neurodegenerative diseases continues to grow. This paper reviews the results of recent and relevant clinical trials examining changes in ¹H-MRS in the most prevalent neurodegenerative diseases.
References
Potulska-Chromik MGA. Neurodegenerative diseases: Alzheimer’s and Parkinson’s disease. Borgis Sp. Z o.o. Published May 27, 2015. Polish.
Kalaria RN, Maestre GE, Arizaga RL, et al. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurology. 2008;7(9):812-826. doi:10.1016/s1474-4422(08)70169-8
Gg K, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clinical Neuropathology. 2010;29(09):271-288. doi:10.5414/npp29271
Cichocka M, Urbanik A. Proton magnetic resonance spectroscopy (1H MRS) spectrum of the adult human brain. Inzynier i Fizyk Medyczny. 2017;6(3):193-196. Polish
Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology. 2017;9(7):a028035. doi:10.1101/cshperspect.a028035
Rzecznik Praw Obywatelskich, Krajowy Mechanizm Prewencji. Raport: Sytuacja osób chorych na chorobę Alzheimera w Polsce. Warszawa: Rzecznik Praw Obywatelskich; 2016.
Kovács GG. Concepts and classification of neurodegenerative diseases. In: Handbook of Clinical Neurology. ; 2018:301-307. doi:10.1016/b978-0-12-802395-2.00021-3
Kovács GG. Current concepts of neurodegenerative diseases. European Medical Journal Neurology. Published online July 14, 2014:10-11. doi:10.33590/emjneurol/10314777
Nous A, Engelborghs S, Smolders I. Melatonin levels in the Alzheimer’s disease continuum: a systematic review. Alzheimer’s Research & Therapy. 2021;13(1). doi:10.1186/s13195-021-00788-6
Silva MVF, De Mello Gomide Loures C, Alves LCV, De Souza LC, Borges KBG, Carvalho MDG. Alzheimer’s disease: risk factors and potentially protective measures. Journal of Biomedical Science. 2019;26(1). doi:10.1186/s12929-019-0524-y
Prince M, et al. World Alzheimer Report 2015: The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International; 2015.
Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Translational Neurodegeneration. 2018;7(1). doi:10.1186/s40035-018-0107-y
Zabłocka A. Alzheimer's disease as an example of a neurodegenerative disease. Postepy Hig Med Dosw. 2006;60. Polish
Balestrino R, Schapira A. Parkinson disease. European Journal of Neurology. 2019;27(1):27-42. doi:10.1111/ene.14108
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nature Reviews Disease Primers. 2017;3(1). doi:10.1038/nrdp.2017.13
Dutkiewicz J, Friedman A. DIAGNOSTYKA ZABURZEŃ AUTONOMICZNYCH W CHOROBIE PARKINSONA DIAGNOSIS OF AUTONOMIC DISORDERS IN PARKINSON’S. Wiad Lek. 2020;73(4):809-813. Polish
Sanford AM. Lewy body dementia. Clinics in Geriatric Medicine. 2018;34(4):603-615. doi:10.1016/j.cger.2018.06.007
Brás J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics Online/Human Molecular Genetics. 2014;23(23):6139-6146. doi:10.1093/hmg/ddu334
Barczak A, Wańska W, Sitek E, Narożańska E, Brockhuis B. Dementia with Lewy bodies – how to recognize?, how to treat?
Pol Przegl Neurol. 2015;11(3):107-116. Polish
Lewy body dementia. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/lewy-body-dementia
Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682. doi:10.1016/s0140-6736(15)00461-4
Flirski M, Sobów T, Kłoszewska I. Treatment of frontotemporal dementia. Postepy Psychiatr Neurol. 2010;19(3):211-217. Polish.
Warren JD, Rohrer JD, Rossor MN. Frontotemporal dementia. BMJ. 2013;347(aug12 3):f4827. doi:10.1136/bmj.f4827
Dayalu P, Albin RL. Huntington Disease. Neurologic Clinics. 2015;33(1):101-114. doi:10.1016/j.ncl.2014.09.003
Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nature Reviews Disease Primers. 2015;1(1). doi:10.1038/nrdp.2015.5
McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. European Journal of Neurology. 2017;25(1):24-34. doi:10.1111/ene.13413
Roos RAC. Huntington’s disease: a clinical review. Orphanet Journal of Rare Diseases. 2010;5(1). doi:10.1186/1750-1172-5-40
Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurology. 2011;10(1):83-98. doi:10.1016/s1474-4422(10)70245-3
Kobelt G, Thompson AJ, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis. 2017;23(8):1123-1136. doi:10.1177/1352458517694432
Kamińska J, Koper OM, Piechal K, Kemona H. Multiple sclerosis - etiology and diagnostic potential. Postępy Higieny I Medycyny Doświadczalnej. 2017;71(1):0. doi:10.5604/01.3001.0010.3836
Ascherio A. Environmental factors in multiple sclerosis. Expert Review of Neurotherapeutics. 2013;13(sup2):3-9. doi:10.1586/14737175.2013.865866
Dobson R, Giovannoni G. Multiple sclerosis – a review. European Journal of Neurology. 2018;26(1):27-40. doi:10.1111/ene.13819
Lassmann H, Brück W, Lucchinetti CF. The Immunopathology of Multiple sclerosis: An Overview. Brain Pathology. 2007;17(2):210-218. doi:10.1111/j.1750-3639.2007.00064.x
Lassmann H. Multiple sclerosis pathology. Cold Spring Harbor Perspectives in Medicine. 2018;8(3):a028936. doi:10.1101/cshperspect.a028936
Brownlee W, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336-1346. doi:10.1016/s0140-6736(16)30959-x
Guz W, Bober Z, Ożóg Ł, et al. Clinical application of advanced neuroimaging techniques – Magnetic Resonance Spectroscopy. European Journal of Clinical and Experimental Medicine. 2017;15(2):133-140. doi:10.15584/ejcem.2017.2.6
Soares D, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clinical Radiology. 2009;64(1):12-21. doi:10.1016/j.crad.2008.07.002
Sibtain N, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clinical Radiology. 2007;62(2):109-119. doi:10.1016/j.crad.2006.09.012
Szuflitowska B. Application of magnetic resonance spectroscopy in the diagnosis of brain tumors. Inżynieria Biomedyczna / Biomedical Engineering. 2016;22. Polish.
Haase A, Frahm J, Hänicke W, Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Physics in Medicine & Biology/Physics in Medicine and Biology. 1985;30(4):341-344. doi:10.1088/0031-9155/30/4/008
Van Der Graaf M. In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. European Biophysics Journal. 2009;39(4):527-540. doi:10.1007/s00249-009-0517-y
Klose U. Measurement sequences for single voxel proton MR spectroscopy. European Journal of Radiology. 2008;67(2):194-201. doi:10.1016/j.ejrad.2008.03.023
P.M. Ruggieri: Practical MR spectroscopy in pediatric neuroradiology, Atlanta, 2000.
R. Magierski, T. Sobów, I. Kłoszewska: Magnetic resonance spectroscopy in degenerative diseases of the central nervous system, Post. Psychiatr. Neurol, 14, 2005, 155-163. Polish
Kantarci K, Petersen RC, Boeve BF, et al. 1 H MR spectroscopy in common dementias. Neurology. 2004;63(8):1393-1398. doi:10.1212/01.wnl.0000141849.21256.ac
Cordón BS, Jurado D, Díaz M. Early Alzheimer´s Disease: findings in structural MRI and MRI-spectroscopy. European Congress of Radiology. March 2014. http://pdf.posterng.netkey.at/download/index.php?module=get_pdf_by_id&poster_id=121643. https://dx.doi.org/10.1594/ecr2014/C-2170
Murray ME, Przybelski SA, Lesnick TG, et al. Early Alzheimer’s disease neuropathology detected by proton MR spectroscopy. the Journal of Neuroscience/the Journal of Neuroscience. 2014;34(49):16247-16255. doi:10.1523/jneurosci.2027-14.2014
Jessen F, Block W, Träber F, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology. 2000;55(5):684-688. doi:10.1212/wnl.55.5.684
Mitolo M, Maserati MS, Capellari S, et al. Predicting conversion from mild cognitive impairment to Alzheimer’s disease using brain 1H-MRS and volumetric changes: A two- year retrospective follow-up study. NeuroImage Clinical. 2019;23:101843. doi:10.1016/j.nicl.2019.101843
Agrawal M, Biswas A. Molecular diagnostics of neurodegenerative disorders. Frontiers in Molecular Biosciences. 2015;2. doi:10.3389/fmolb.2015.00054
Guan J, Yu R, Wen Y, et al. Detection and application of neurochemical profile by multiple regional 1H‐MRS in Parkinson’s disease. Brain and Behavior. 2017;7(9). doi:10.1002/brb3.792
Camicioli R, Hanstock CC, Bouchard T, Gee M, Fisher N, Martin W. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson’s disease. Movement Disorders. 2007;22(3):382-386. doi:10.1002/mds.21288
Barbagallo G, Arabia G, Morelli M, et al. Thalamic neurometabolic alterations in tremulous Parkinson’s disease: A preliminary proton MR spectroscopy study. Parkinsonism & Related Disorders (Online)/Parkinsonism & Related Disorders. 2017;43:78-84. doi:10.1016/j.parkreldis.2017.07.028
Mazuel L, Chassain C, Jean B, et al. Proton MR spectroscopy for diagnosis and evaluation of treatment efficacy in Parkinson Disease. Radiology. 2016;278(2):505-513. doi:10.1148/radiol.2015142764
Zhong X, Shi H, Shen Z, et al. 1H-Proton Magnetic Resonance Spectroscopy Differentiates Dementia with Lewy Bodies from Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2014;40(4):953-966. doi:10.3233/jad-131517
Zhang B, Ferman TJ, Boeve BF, et al. MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer’s Disease. Journal of Neuroimaging. 2014;25(2):269-274. doi:10.1111/jon.12138
Kantarci K. Proton MRS in mild cognitive impairment. Journal of Magnetic Resonance Imaging. 2013;37(4):770-777. doi:10.1002/jmri.23800
Graff‐Radford J, Boeve BF, Murray ME, et al. Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging. 2014;35(6):1483-1490. doi:10.1016/j.neurobiolaging.2014.01.001
Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology. 1997;203(3):829-836. doi:10.1148/radiology.203.3.9169712
Kizu O, Yamada K, Ito H, Nishimura T. Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy. Neuroradiology. 2004;46(4):277-281. doi:10.1007/s00234-004-1167-5
Kantarci K, Petersen RC, Boeve BF, et al. 1 H MR spectroscopy in common dementias. Neurology. 2004;63(8):1393-1398. doi:10.1212/01.wnl.0000141849.21256.ac
Mihara M, Hattori N, Abe K, Sakoda S, Sawada T. Magnetic resonance spectroscopic study of Alzheimer’s disease and frontotemporal dementia/Pick complex. NeuroReport/Neuroreport. 2006;17(4):413-416. doi:10.1097/01.wnr.0000203353.52622.05
Murley AG, Tsvetanov KA, Rouse MA, et al. Proton magnetic resonance spectroscopy in frontotemporal lobar degeneration-related syndromes. Neurobiology of Aging. 2022;111:64-70. doi:10.1016/j.neurobiolaging.2021.10.012
Šarac H, Ozretić D, Henigsberg N, Hrabač P, Bagarić I, Bagarić-Krakan L. PROTON MAGNETIC RESONANCE SPECTROSCOPY IN HUNTINGTON’S DISEASE ACCOMPANYING NEUROBORRELIOSIS. Psychiatria Danubina. 2017;29(2):226-230. doi:10.24869/psyd.2017.226
Adanyeguh I, Monin ML, Rinaldi D, et al. Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy. NMR in Biomedicine. 2018;31(3). doi:10.1002/nbm.3880
Padowski JM, Weaver KE, Richards TL, et al. Neurochemical correlates of caudate atrophy in Huntington’s disease. Movement Disorders. 2014;29(3):327-335. doi:10.1002/mds.25801
Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 2010;75(19):1702-1710. doi:10.1212/wnl.0b013e3181fc27e4
Swanberg KM, Landheer K, Pitt D, Juchem C. Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker. Frontiers in Neurology. 2019;10. doi:10.3389/fneur.2019.01173
Sun J, Song H, Yang Y, et al. Metabolic changes in normal appearing white matter in multiple sclerosis patients using multivoxel magnetic resonance spectroscopy imaging. Medicine. 2017;96(14):e6534. doi:10.1097/md.0000000000006534
Aboul‐Enein F, Krs̆S̆Ák M, Höftberger R, Prayer D, Kristoferitsch W. Reduced NAA-Levels in the NAWM of Patients with MS Is a Feature of Progression. A Study with Quantitative Magnetic Resonance Spectroscopy at 3 Tesla. PloS One. 2010;5(7):e11625. doi:10.1371/journal.pone.0011625
Mader I, Roser W, Kappos L, et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. American Journal of Neuroradiology. 2000;21(7):1220-1227. http://www.ajnr.org/content/21/7/1220.full.pdf.
Farez M, Crivelli L, Leiguarda R, Correale J. Decision-making impairment in patients with multiple sclerosis: a case-control study. BMJ Open. 2014;4(7):e004918. doi:10.1136/bmjopen-2014-004918
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Katarzyna Szmyt, Maciej Superson, Klaudia Wilk-Trytko, Katarzyna Szymańska, Kamil Walczak, Sylwia Samojedny, Wiktoria Mika, Julia Krasnoborska, Julia Zarębska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 349
Number of citations: 0
